First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart…
As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access…
HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical…
AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company…
On track for topline data from CAN-2409 phase 3 in localized intermediate/high risk prostate cancer, expected in Q4 2024Results from…
WARREN, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech…
CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company…
David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a New ChairLONDON, March…
- New 12-month data from the Phase 3 BOND-003 trial to be featured in an oral presentation in the Paradigm-shifting,…
CUPERTINO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage…